A Phase 2 interventional study of Dupilumab and Placebo in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 84 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-28.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 3 that started in 2013, is one of 7 in phase 2, and was the 4th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 380 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 7th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2013, is one of 8 in phase 2, and was the 5th registered.
Regeneron Pharmaceuticals’s Dermatitis, Atopic studies by the year they started, since 2011.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Regeneron Pharmaceuticals’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).
The inclusion criteria included, but were not limited to, the following:
The exclusion criteria included, but were not limited to, the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.
Drug: Placebo
Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
Drug: Dupilumab
Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.
Drug: Dupilumab · Drug: Placebo
Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.
Drug: Dupilumab · Drug: Placebo
Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
Drug: Dupilumab · Drug: Placebo
Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
Drug: Dupilumab · Drug: Placebo
Also known as: REGN668, SAR231893, Dupixent
Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Time frame: Baseline to Week 16
Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 16
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.
Time frame: Week 16
Percentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 16
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic success is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score reduction from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.
Time frame: Week 16
Percent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16
Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).
Time frame: Baseline to Week 16
Absolute Change in Peak Weekly Averaged Pruritus NRS From Baseline to Week 16
Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).
Time frame: Baseline to Week 16
Absolute Change in EASI Score From Baseline to Week 16
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Time frame: Baseline to Week 16
Percent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).
Time frame: Baseline to Week 16
Absolute Change in SCORAD Scores From Baseline to Week 16
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).
Time frame: Baseline to Week 16
Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score (EASI-50, EASI-75 and EASI-90 Respectively) at Week 16
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in EASI score respectively from baseline to Week 16.
Time frame: Week 16
Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in SCORAD score respectively from baseline to Week 16.
Time frame: Week 16
Percent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16
POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).
Time frame: Baseline to Week 16
Absolute Change in POEM Scores From Baseline to Week 16
POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).
Time frame: Baseline to Week 16
Changes in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) From Baseline to Week 16
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0=none, 1=mild, 2=moderate and 3=severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).
Time frame: Baseline to Week 16
Changes in GISS Cumulative Score From Baseline to Week 16
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none,1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).
Time frame: Baseline to Week 16
The study was conducted at 95 study sites in 7 countries. A total of 452 participants were screened between 15 May 2013 and 10 January 2014. 380 participants were randomized and 379 were treated. 72 participants were screen failures mainly due to exclusion criteria met and inclusion criteria not met.
| Milestone | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Started | 63 | 64 | 62 | 65 | 65 | 61 |
| Treated | 63 | 64 | 61 | 65 | 65 | 61 |
| Completed | 52 | 52 | 34 | 55 | 42 | 42 |
| Not completed | 11 | 12 | 28 | 10 | 23 | 19 |
| Withdrew: Withdrawal by subject | 6 | 3 | 4 | 3 | 2 | 2 |
| Withdrew: Lack of efficacy | 1 | 1 | 5 | 0 | 7 | 9 |
| Withdrew: Physician decision | 1 | 3 | 1 | 3 | 4 | 1 |
| Withdrew: Adverse event | 2 | 1 | 3 | 1 | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 | 3 | 0 | 3 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other than specified above | 0 | 2 | 11 | 3 | 5 | 3 |
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
| Percent change | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16 | -75.5 ± 26.86 | -70.5 ± 35.09 | -67.4 ± 31.97 | -64.9 ± 37.21 | -46.7 ± 41.96 | -20.2 ± 46.15 |
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.
| Percentage of participants | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 16 | 33.3 (21.95 to 46.34) | 29.7 (18.91 to 42.42) | 27.9 (17.15 to 40.83) | 21.5 (12.31 to 33.49) | 12.3 (5.47 to 22.82) | 1.6 (0.04 to 8.80) |
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic success is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score reduction from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.
| Percentage of participants | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 16 | 50.8 (37.89 to 63.62) | 46.9 (34.28 to 59.77) | 42.6 (30.04 to 55.94) | 35.4 (23.92 to 48.23) | 20.0 (11.10 to 31.77) | 9.8 (3.70 to 20.19) |
Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).
| Percent change | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Percent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16 | -52.85 ± 31.368 | -46.22 ± 31.964 | -40.6 ± 33.073 | -38.69 ± 38.366 | -21.47 ± 32.952 | -0.43 ± 38.423 |
Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).
| units on a scale | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Baseline | 6.54 ± 1.54 | 6.74 ± 2.072 | 6.98 ± 2.315 | 6.84 ± 1.853 | 6.71 ± 1.882 | 6.34 ± 1.832 |
| Week 16 | 3.07 ± 2.148 | 3.64 ± 2.388 | 4.21 ± 2.763 | 3.99 ± 2.449 | 5.26 ± 2.465 | 6.05 ± 2.312 |
| Change at Week 16 | -3.48 ± 2.32 | -3.16 ± 2.467 | -2.77 ± 2.595 | -2.79 ± 2.609 | -1.46 ± 2.038 | -0.27 ± 2.28 |
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
| Units on a scale | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Baseline | 30.1 ± 11.23 | 33.8 ± 14.52 | 32.9 ± 15.5 | 29.4 ± 11.48 | 32.2 ± 13.49 | 32.9 ± 13.77 |
| Week 16 | 7.2 ± 8.83 | 10.7 ± 12.89 | 10.9 ± 12.41 | 9.8 ± 11.16 | 17.4 ± 15.28 | 25.6 ± 18.32 |
| Change at Week 16 | -23.1 ± 1.70 | -21.1 ± 1.68 | -20.7 ± 1.71 | -20.4 ± 1.62 | -13.8 ± 1.64 | -5.8 ± 1.71 |
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).
| Percent change | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Percent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16 | -56.9 ± 4.12 | -51.2 ± 4.05 | -46.0 ± 4.12 | -48.8 ± 3.95 | -26.6 ± 3.98 | -13.8 ± 4.14 |
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).
| units on a scale | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Absolute Change in SCORAD Scores From Baseline to Week 16 | -38.2 ± 2.76 | -34.4 ± 2.71 | -30.9 ± 2.76 | -33.1 ± 2.64 | -18.0 ± 2.66 | -10.5 ± 2.77 |
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in EASI score respectively from baseline to Week 16.
| Percentage of participants | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Reduction of 50% | 82.5 (70.90 to 90.95) | 78.1 (66.03 to 87.49) | 62.3 (48.96 to 74.39) | 70.8 (58.17 to 81.40) | 44.6 (32.27 to 57.47) | 29.5 (18.52 to 42.57) |
| Reduction of 75% | 60.3 (47.20 to 72.43) | 53.1 (40.23 to 65.72) | 55.7 (42.45 to 68.45) | 49.2 (36.60 to 61.93) | 29.2 (18.60 to 41.83) | 11.5 (4.74 to 22.22) |
| Reduction of 90% | 36.5 (24.73 to 49.60) | 29.7 (18.91 to 42.42) | 31.1 (19.90 to 44.29) | 29.2 (18.60 to 41.83) | 15.4 (7.63 to 26.48) | 3.3 (0.40 to 11.35) |
SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in SCORAD score respectively from baseline to Week 16.
| Percentage of participants | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Reduction of 50% | 68.3 (55.3 to 79.4) | 59.4 (46.4 to 71.5) | 52.5 (39.3 to 65.4) | 55.4 (42.5 to 67.7) | 26.2 (16.0 to 38.5) | 19.7 (10.6 to 31.8) |
| Reduction of 75% | 23.8 (14.0 to 36.2) | 25.0 (15.0 to 37.4) | 16.4 (8.2 to 28.1) | 21.5 (12.3 to 33.5) | 7.7 (2.5 to 17.0) | 3.3 (0.4 to 11.3) |
| Reduction of 90% | 6.3 (1.8 to 15.5) | 6.3 (1.7 to 15.2) | 4.9 (1.0 to 13.7) | 3.1 (0.4 to 10.7) | 3.1 (0.4 to 10.7) | 0.0 (0.0 to 5.9) |
POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).
| Percent change | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Percent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16 | -57.3 ± 4.52 | -44.0 ± 4.44 | -49.2 ± 5.54 | -46.6 ± 4.33 | -14.2 ± 4.35 | 0.2 ± 4.61 |
POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).
| units on a scale | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Absolute Change in POEM Scores From Baseline to Week 16 | -12.1 ± 0.88 | -9.8 ± 0.87 | -10.4 ± 0.89 | -9.9 ± 0.85 | -3.3 ± 0.85 | -1.1 ± 0.90 |
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0=none, 1=mild, 2=moderate and 3=severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).
| units on a scale | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Erythema | -0.9 ± 0.10 | -0.9 ± 0.10 | -0.8 ± 0.10 | -0.8 ± 0.10 | -0.4 ± 0.10 | -0.2 ± 0.10 |
| Infiltration/Papulation | -1.2 ± 0.11 | -1.1 ± 0.11 | -1.0 ± 0.11 | -1.1 ± 0.10 | -0.6 ± 0.11 | -0.3 ± 0.11 |
| Excoriations | -1.4 ± 0.11 | -1.4 ± 0.11 | -1.1 ± 0.11 | -1.3 ± 0.11 | -0.6 ± 0.11 | -0.4 ± 0.11 |
| Lichenification | -1.1 ± 0.12 | -1.1 ± 0.11 | -1.0 ± 0.12 | -1.1 ± 0.11 | -0.7 ± 0.11 | -0.3 ± 0.12 |
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none,1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).
| units on a scale | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Changes in GISS Cumulative Score From Baseline to Week 16 | -4.6 ± 0.38 | -4.5 ± 0.37 | -3.9 ± 0.38 | -4.3 ± 0.37 | -2.3 ± 0.37 | -1.2 ± 0.38 |
Collected over Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Baseline to Week 32) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dupilumab 300 mg qw | — | 1/63 (1.6%) | 35/63 (55.6%) |
| Dupilumab 300 mg q2w | — | 2/64 (3.1%) | 34/64 (53.1%) |
| Dupilumab 200 mg q2w | — | 1/61 (1.6%) | 34/61 (55.7%) |
| Dupilumab 300 mg q4w | — | 3/65 (4.6%) | 39/65 (60%) |
| Dupilumab 100 mg q4w | — | 5/65 (7.7%) | 38/65 (58.5%) |
| Placebo | — | 4/61 (6.6%) | 38/61 (62.3%) |
| Event | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/63 | 1/64 | 0/61 | 0/65 | 4/65 | 1/61 |
| TachycardiaCardiac disorders | 0/63 | 0/64 | 1/61 | 0/65 | 0/65 | 0/61 |
| Hip dysplasiaCongenital, familial and genetic disorders | 0/63 | 0/64 | 0/61 | 0/65 | 0/65 | 1/61 |
| Anaphylactic shockImmune system disorders | 0/63 | 0/64 | 1/61 | 0/65 | 0/65 | 0/61 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/63 | 0/64 | 0/61 | 0/65 | 0/65 | 1/61 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/63 | 0/64 | 1/61 | 0/65 | 0/65 | 0/61 |
| Abortion inducedSurgical and medical procedures | 0/63 | 0/64 | 0/61 | 0/65 | 0/65 | 1/61 |
| Viral infectionInfections and infestations | 1/63 | 0/64 | 0/61 | 0/65 | 0/65 | 0/61 |
| SyncopeNervous system disorders | 0/63 | 1/64 | 0/61 | 0/65 | 0/65 | 0/61 |
| CellulitisInfections and infestations | 0/63 | 0/64 | 0/61 | 0/65 | 1/65 | 0/61 |
| Event | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 16/63 | 16/64 | 16/61 | 21/65 | 20/65 | 16/61 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 8/63 | 13/64 | 8/61 | 10/65 | 11/65 | 10/61 |
| Upper respiratory tract infectionInfections and infestations | 5/63 | 6/64 | 2/61 | 5/65 | 5/65 | 11/61 |
| HeadacheNervous system disorders | 8/63 | 5/64 | 9/61 | 5/65 | 7/65 | 2/61 |
| Conjunctivitis allergicEye disorders | 3/63 | 2/64 | 6/61 | 3/65 | 1/65 | 2/61 |
| Urinary tract infectionInfections and infestations | 0/63 | 3/64 | 6/61 | 3/65 | 2/65 | 2/61 |
| Back painMusculoskeletal and connective tissue disorders | 2/63 | 2/64 | 0/61 | 2/65 | 3/65 | 5/61 |
| Herpes simplexInfections and infestations | 1/63 | 2/64 | 3/61 | 1/65 | 5/65 | 0/61 |
| Oral herpesInfections and infestations | 0/63 | 3/64 | 2/61 | 3/65 | 5/65 | 0/61 |
| VomitingGastrointestinal disorders | 1/63 | 0/64 | 4/61 | 0/65 | 0/65 | 3/61 |
Baseline population included safety analysis set (SAF) that included all randomized participants who received any investigational product and analyzed as treated. One participant randomized into Dupilumab 200 mg q2w arm was not treated and hence, excluded from the baseline population.
| Age, Continuous(years) | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 36.2 ± 10.74 | 39.4 ± 12.06 | 35.8 ± 14.90 | 36.8 ± 10.77 | 36.6 ± 11.55 | 37.2 ± 13.10 | 37.0 ± 12.06 |
| Sex: Female, Male(Participants) | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | Dupilumab 200 mg q2w | Dupilumab 300 mg q4w | Dupilumab 100 mg q4w | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 20 | 23 | 25 | 25 | 31 | 21 | 145 |
| Male | 43 | 41 | 36 | 40 | 34 | 40 | 234 |
The record gives a start of May 2013, a primary completion of May 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 3 years 3 months after primary completion. A results delay was requested in Apr 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab